Myasthenia Gravis: Steroid-Sparing Agent Selection Between Guideline Sequencing and a Label Technicality
A single patient, newly diagnosed with generalized myasthenia gravis and already showing real steroid toxicity risk. The disagreement is whether a fast biologic being technically on-label changes where it belongs in the standard treatment sequence.
P.N., a 44-year-old elementary school music teacher, noticed her arms tiring mid-song at the piano weeks before double vision made the diagnosis unavoidable, an early symptom she'd mostly attributed to end-of-semester fatigue until she found herself unable to hold a downbeat through a full rehearsal. Generalized, AChR-antibody-positive myasthenia gravis was confirmed six weeks ago, and prednisone 40 milligrams daily has brought her MG-ADL score down from 11 to 6 — real improvement, but not remission, and not without cost. Her baseline bone density scan, drawn before starting steroids given her family history of osteoporosis, already showed osteopenia, and she has asked directly how long she'll need to stay on a dose that high. Continuing high-dose prednisone for the months a traditional steroid-sparing agent typically needs to take effect is not a neutral choice for her specifically.
The decision in front of the team is which steroid-sparing agent to add, and the honest answer depends on reading the actual trials, not just the drug classes, against each other. Azathioprine remains the guideline-standard first-line agent internationally — cheap, familiar, well-studied — but its own onset runs six to twelve months, meaning P.N. would stay on high-dose prednisone through most of that window. Efgartigimod's ADAPT trial, by contrast, showed a roughly 68% clinical responder rate in its first treatment cycle against 30% for placebo, with benefit apparent within one to two weeks — and critically, ADAPT enrolled a broad generalized AChR-positive population, not only patients who had already failed other immunosuppressants, which is the distinction that actually determines whether using it now, rather than after azathioprine fails, is on-label or not.
Guideline sequencing against a label technicality
I'd start efgartigimod now, not azathioprine. People hear "biologic" and assume it must be reserved for refractory disease, but ADAPT didn't require prior immunosuppressant failure to enroll — this is on-label first-line use for her, not an off-label reach. Given her osteopenia, every additional month at 40 milligrams of prednisone is a real cost, and efgartigimod's own trial showed response within one to two weeks against a six-to-twelve-month wait for azathioprine to take hold.
You're right that ADAPT's enrollment doesn't technically require prior treatment failure — I want to be clear I'm not disputing that. But international MG consensus guidelines still name azathioprine as the default first-line steroid-sparing agent, and that sequencing exists for a reason beyond cost alone: for most AChR-positive patients, azathioprine achieves durable long-term control without asking the health system, or her, to commit to a therapy running well into six figures annually indefinitely.
Treating "technically on-label" as equivalent to "the appropriate first choice" skips over exactly the guideline sequencing this field built specifically to reserve costlier, scarcer agents for patients who actually need them — and there's a real, manageable safety step here too: we should check her TPMT status before starting azathioprine, since severe myelosuppression in TPMT-deficient patients is a known, testable risk, not a reason to avoid the drug outright.
I don't think this actually has to be either-or. Start azathioprine today, with TPMT testing sent first, for durable long-term control — and add a short, explicitly time-limited efgartigimod bridge specifically to accelerate her prednisone taper while azathioprine's slow onset catches up. Stop the efgartigimod once azathioprine is established and her steroid dose is down.
That gets her off high-dose prednisone faster than azathioprine alone would, without committing to indefinite biologic cost, and it doesn't require deciding in advance which of you is right about long-term sequencing — the bridge is bounded and reassessed, not open-ended.
Agreed: azathioprine started after TPMT testing returned normal, with a bounded efgartigimod bridge added to accelerate the prednisone taper. Prednisone tapering begins as her MG-ADL score allows.
Not agreed: whether biologics like efgartigimod should move earlier in the standard sequencing for future patients given ADAPT's actual enrollment criteria, independent of P.N.'s specific situation — left as an open guideline question, not settled by today's individualized plan.